Free Trial
NYSEAMERICAN:IGC

IGC Pharma 11/12/2024 Earnings Report

IGC Pharma logo
$0.32 0.00 (-1.24%)
Closing price 05/6/2026 04:10 PM Eastern
Extended Trading
$0.32 0.00 (-0.69%)
As of 05/6/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IGC Pharma EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.03
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

IGC Pharma Revenue Results

Actual Revenue
$0.41 million
Expected Revenue
$0.29 million
Beat/Miss
Beat by +$120.00 thousand
YoY Revenue Growth
N/A

IGC Pharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

IGC Pharma Earnings Headlines

Cannabis funding opens
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More IGC Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email.

About IGC Pharma

IGC Pharma (NYSEAMERICAN:IGC), a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

View IGC Pharma Profile